P.M. Illam, V.K. Singh, Priya et al.
Journal of Organometallic Chemistry 951 (2021) 122008
solid. Yield: 624 mg (2.10 mmol, 73.0%). 1H NMR (400 MHz, CDCl3)
δ 11.02 (s, 1H), 7.79 (s, 2H), 7.44 (s, 1H), 7.41 (d, J = 8.2 Hz, 1H),
7.29 (m, 1H), 7.02 (d, J = 8.3 Hz, 1H), 4.63 (q, J = 7.2 Hz, 2H),
3.94 (s, 3H), 1.67 (t, J = 7.2 Hz, 3H) ppm. 13C{1H} NMR (101 MHz,
CDCl3) δ 161.2, 135.9, 135.5, 131.3, 122.7, 120.8, 116.8, 113.3, 107.3,
56.6, 45.8, 15.9 ppm.
4.4.2. Synthesis of complex 6
Using the imidazolium salt 1e (100 mg, 0.32 mmol), the gen-
eral procedure was followed and the complex 6 was isolated as an
orange solid. Yield 132 mg (0.25 mmol, 78.0%). 1H NMR (400 MHz,
CDCl3) δ 8.94 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.41 (s, 1H), 7.12
(d, J = 8.6 Hz, 1H), 7.09 (s, 1H), 5.66 (d, J = 5.8 Hz, 1H), 5.62 (d,
J = 5.5 Hz, 1H), 5.55 (d, J = 5.8 Hz, 1H), 5.39 (s, J = 5.8 Hz, 1H),
4.59 (dd, J = 14.0, 7.0 Hz, 1H), 4.48 (dd, J = 13.7, 7.1 Hz, 1H), 2.24
(m, 1H), 2.18 (s, 3H), 1.65 (t, J = 7.3 Hz, 3H), 0.91 (d, J = 6.8 Hz,
3H), 0.75 (d, J = 6.8 Hz, 3H) ppm. 13C{1H} NMR (101 MHz, CDCl3)
δ 189.2, 164.7, 150.9, 143.8, 136.3, 121.1, 119.4, 115.3, 110.5, 105.3,
101.4, 93.2, 90.8, 88.6, 84.5, 46.0, 31.3, 23.1, 21.9, 19.7, 16.7 ppm.
4.3.5. Synthesis of
3-ethyl-1-(3-(trifluoromethyl)phenyl)-1H-imidazol-3-ium bromide
(1h). Using compound
H (500 mg, 2.35 mmol) and bro-
moethane (2.0 mg, 19 mmol) following the similar procedure for
1g, the imidazolium salt 1h was isolated as air stable white solid.
Yield: 672 mg (2.09 mmol, 89.0%). 1H NMR (400 MHz, CDCl3) δ
11.06 (s, 1H), 8.21 (s, 1H), 8.03 (s, 2H), 7.96 (s, 1H), 7.70 (d, J = 4.1
Hz, 2H), 4.59 (q, J = 7.3 Hz, 2H), 1.63 (t, J = 7.3 Hz, 3H) ppm.
13C{1H} NMR (101 MHz, CDCl3) δ 135.9, 135.0, 132.9, 132.5, 131.6,
126.9, 125.9, 123.6, 121.1, 118.9, 45.9, 15.7 ppm.
4.4.3. Synthesis of complex 7
Using the imidazolium salt 1f (100 mg, 0.374 mmol), the gen-
eral procedure was followed and the complex 7 was isolated as
a yellow solid. Yield 148 mg (0.29 mmol, 79.0%). 1H NMR (500
MHz, CDCl3) δ 7.95 (d, J = 7.5 Hz, Ar-H, 1H), 7.34 (s, 1H), 7.00 (d,
J = 2.0 Hz, Imidazole-H, 1H), 6.90 (s, 1H), 6.79 (d, J = 7.5 Hz, Ar-H,
1H), 5.56 (d, J = 6.0 Hz, p-cymene−Ph,1H), 5.52 (d, J = 6.5 Hz, p-
cymene−Ph, 1H), 5.39 (d, J = 6.0 Hz, p-cymene−Ph, 1H), 5.30 (d,
J = 6.5 Hz, p-cymene−Ph, 1H), 4.58 (dq, J = 14.7, 7.4 Hz, NCH2CH3,
1H), 4.48 (dq, J = 14.6, 7.3 Hz, NCH2CH3, 1H), 2.33 (s, Ph-Me, 3H),
2.26 (sept, J = 6.9 Hz, p-cymene−iPr, 1H), 2.12 (s, p-cymene−Me,
3H), 1.62 (t, J = 7.4 Hz, NCH2CH3, 3H), 0.93 (d, J = 6.9 Hz, p-
cymene−iPr, 3H), 0.77 (d, J = 6.9 Hz, p-cymene−iPr, 3H) ppm.
13C{1H} NMR (126 MHz, CDCl3) δ 187.2, 157.6, 145.4, 141.6, 131.7,
125.5, 119.6, 114.5, 112.2, 103.0, 100.2, 92.4, 89.9, 87.4, 83.7, 45.7,
31.2, 23.2, 21.8, 21.2, 19.7, 16.8 ppm.
4.3.6. Synthesis of 3-ethyl-1-(3-nitrophenyl)-1H-imidazol-3-ium
bromide
(1i). Using compound I (500 mg, 2.64 mmol) and bromoethane
(2.3 g, 21 mmol) following the similar procedure for 1g, the imi-
dazolium salt 1i was isolated as air stable pale yellow solid. Yield:
590 mg (1.98 mmol, 75.0%). 1H NMR (500 MHz, DMSO-d6) δ 10.02
(s, 1H), 8.73 (s, 1H), 8.47 (s, 1H), 8.43 (d, J = 8.1 Hz, 1H), 8.29
(d, J = 7.3 Hz, 1H), 8.12 (s, 1H), 7.98 (t, J = 8.2 Hz, 1H), 4.32
(q, J = 7.2 Hz, 2H), 1.53 (t, J = 7.3 Hz, 3H) ppm. 13C{1H} NMR
(126 MHz, DMSO-d6) δ 148.4, 136.1, 135.6, 131.7, 128.4, 124.3, 123.1,
121.3, 117.4, 44.9, 14.8 ppm.
4.4.4. Synthesis of complex 8
4.3.7. Synthesis of 4-ethyl-1-phenyl-1H-1,2,4-triazol-4-ium bromide
(1j). Using compound J (600 mg, 4.13 mmol) and bromoethane
(3.6 g, 33 mmol) following the similar procedure for 1g, the imida-
zolium salt 1j was isolated as air stable white solid. Yield: 808 mg
(3.18 mmol, 77%). 1H NMR (400 MHz, CDCl3) δ 12.17 (s, 1H), 9.54
(s, 1H), 8.02 (d, J = 7.7 Hz, 2H), 7.51 (q, J = 9.9, 8.3 Hz, 3H), 4.76
(q, J = 7.4 Hz, 2H), 1.72 (t, J = 7.4 Hz, 3H) ppm. 13C{1H} NMR (126
MHz, CDCl3) δ 144.3, 140.9, 140.8, 134.9, 131.0, 130.4, 120.6, 44.8,
15.9 ppm.
Using the imidazolium salt 1h (100 mg, 0.311 mmol), the gen-
eral procedure was followed and the complex 8 was isolated as a
dark yellow solid. Yield: 140 mg (0.25 mmol, 80.0%). 1H NMR (500
MHz, CDCl3) δ 8.21 (d, J = 7.7 Hz, Ar-H, 1H), 7.41 (s, 1H), 7.24 (s,
1H), 7.17 (d, J = 7.7 Hz, Ar-H, 1H), 7.06 (s, 1H), 5.58 (m, J = 4.6
Hz, p-cymene−Ph, 2H), 5.46 (d, J = 6.0 Hz, p-cymene−Ph, 1H),
5.36 (d, J = 5.9 Hz, p-cymene−Ph, 1H), 4.58 (dq, J = 14.5, 7.4 Hz,
NCH2CH3, 1H), 4.48 (dq, J = 14.2, 7.2 Hz, NCH2CH3, 1H), 2.24 (m,
J = 6.9 Hz, p-cymene−iPr, 1H), 2.14 (s, p-cymene−Me, 3H), 1.63 (t,
J = 7.3 Hz, NCH2CH3, 3H), 0.92 (d, J = 6.9 Hz, p-cymene−iPr, 3H),
0.76 (d, J = 6.8 Hz, p-cymene−iPr, 3H) ppm. 13C{1H} NMR (126
MHz, CDCl3) δ 187.5, 170.1, 145.7, 142.0, 120.6 (q, J = 3.5 Hz), 120.4,
114.8, 107.2 (q, J = 3.5 Hz), 104.3, 101.2, 92.7, 90.6, 88.2, 84.4, 45.8,
31.2, 23.1, 21.8, 19.7, 16.8 ppm. 19 F {1H}NMR (471 MHz, CDCl3) δ
-61.35 (s) ppm.
4.4. General procedure for the synthesis of orthometalated
RuII-complexes 2, 6 and 7-10
To a pressure tube equipped with a magnetic stirring bar,
azolium salt (1 equiv.), [Ru(p-cymene)Cl2]2 (0.5 equiv.), Cs2CO3 (2
equiv.), NaBr (3 equiv.) were added along with dry THF and stirred
for 24 h at 70°C. After cooling, the solvent was dried in high vacuo
and the residue was dissolved in dichloromethane. The obtained
dark brown suspension was then filtered through neutral alumina
to get a clear yellow solution which was further concentrated and
precipitated using n-hexane to get air and moisture stable yellow
to orange solids.
4.4.5. Synthesis of complex 9
Using the imidazolium salt 1i (100 mg, 0.335 mmol), the gen-
eral procedure was followed and the complex 8 was isolated as
a brown solid. Yield: 122 mg (0.23 mmol, 69.0%). 1H NMR (500
MHz, CDCl3) δ 8.27 (d, J = 8.2 Hz, Ar-H, 1H), 7.89 (d, J = 2.2
Hz, Imidazole-H, 1H), 7.82 (dd, J = 8.2, 2.2 Hz, 1H), 7.48 (d,
J = 2.1 Hz, 1H), 7.11 (d, J = 2.1 Hz, 1H), 5.64 (m, 2H), 5.52 (d,
J = 5.5 Hz, p-cymene−Ph,1H), 5.40 (d, J = 5.9 Hz, p-cymene−Ph,
1H), 4.57 (dq, J = 14.8, 7.4 Hz, NCH2CH3, 1H), 4.47 (dq, J = 14.6,
7.3 Hz, NCH2CH3,1H), 2.24 (m, p-cymene−iPr, 1H), 2.17 (s, p-
cymene−Me,3H), 1.65 (t, J = 7.4 Hz, NCH2CH3, 3H), 0.91 (d, J = 6.9
Hz, p-cymene−iPr, 3H), 0.75 (d, J = 6.9 Hz, p-cymene−iPr, 3H)
ppm. 13C{1H} NMR (126 MHz, CDCl3) δ 187.6, 181.1, 145.9, 144.4,
141.9, 120.9, 118.6, 115.1, 105.7, 105.2, 101.8, 93.31, 91.2, 89.0, 85.0,
45.9, 31.2, 23.1, 21.9, 19.7, 16.7 ppm.
4.4.1. Synthesis of complex 3
Using the imidazolium salt 1b (100 mg, 0.32 mmol), the general
procedure was followed and the complex 3 was isolated as a pale-
yellow solid. Yield 112 mg (0.22 mmol, 70.0%) 1H NMR (400 MHz,
CDCl3) δ 7.91 (s, 1H), 7.32 (s, 1H), 7.00 (s, 1H), 6.95 (d, J = 7.8 Hz,
1H), 6.73 (d, J = 7.7 Hz, 1H), 5.54 (dd, J = 9.9, 6.0 Hz, 2H), 5.41 (d,
J = 5.9 Hz, 1H), 5.33 (d, J = 5.8 Hz, 1H), 4.58 (dt, J = 14.0, 7.3 Hz,
1H), 4.47 (dd, J = 13.7, 7.2 Hz, 1H), 2.35 (s, 3H), 2.30–2.17 (m, 1H),
2.13 (s, 2H), 1.62 (t, J = 7.3 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H), 0.76 (d,
J = 6.9 Hz, 3H) ppm. 13C{1H} NMR (101 MHz, CDCl3) δ 186.5, 162.1,
143.3, 142.7, 133.4, 123.0, 119.6, 114.5, 110.6, 103.6, 99.8, 92.3, 89.9,
87.3, 84.0, 45.6, 31.2, 23.1, 21.9, 21.6, 19.7, 16.8 ppm.
4.4.6. Synthesis of complex 10
Using the imidazolium salt 1j (100 mg, 0.393 mmol), the gen-
eral procedure was followed and the complex 10 was isolated as a
8